PAGE 1
PLEASE READ: THE
FOLLOWING FILES on this page ARE ARCHIVED FILES AS
WE HAVE MOVED TO ANOTHER FORMAT TO PRESENT NEW INFORMATION.
5/2000 Data
presented from The 52nd Annual Meeting of the American Academy of Neurology
Data
presented from American
Neurological Association:
6/2000 Data
presented from The
Tenth Meeting of the European Neurological Society
9/2000 Data
presented from The 16th
Congress of the European Committee for Treatment and Research in Multiple
Sclerosis
Data Presented From
European Consortium of Treatment and Research in Multiple
Sclerosis -- Early treatment in MS
Data Presented from
7/98
AastromReplicell(TM) Cell Production System for Stem
Cell therapies in the treatment of cancer, autoimmune and other diseases.
3/96 Acyclovir treatment of
relapsing-remitting multiple sclerosis. A randomized, placebo-controlled,
double-blind study.
The safety of dental Amalgam restorations has been challenged with assertions that mercury released
from amalgam produces mercury poisoning, and is thus responsible for diverse
symptoms of impaired health as well as disease states such as Multiple Sclerosis
(MS).
7/99 Elan announced Preliminary
Results of a Phase II clinical study evaluating Antegren(R) (natalizumab),
a humanized monoclonal antibody, in the treatment of acute exacerbation in patients
with multiple sclerosis ("MS")
1/16/01 Avonex
Treatment with AVONEX reduced the progression of disability of secondary
progressive MS by 27 percent versus treatment with placebo.
10/25/00 Optic
Neuritis
9/00 Champs
Study! A new study shows that
even in people who have not yet developed MS, but have very early signs of the
disease, treatment with Avonex® can delay progression to full-blown
MS.
4/5/00 A New
Source of Information and Support Designed to Help All People with MS and
their Care Partners to Take an Active Role in the Management of MS.
2/1/00 Biogen's Avonex (Interferon
beta-1a) Shows a Beneficial Effect On Delaying the
Development of Multiple Sclerosis.
10/99 The Avonex
Alliance and Personal Stories
3/3/99
CAMBRIDGE, MA (March 1, 1999) -- Biogen, Inc. (NASDAQ/BGEN) said that
today’s U.S. Food and Drug Administration (FDA) ruling
Upholding
Orphan Drug exclusivity for the Company’s AVONEX® (Interferon
beta-1a), as well Berlex Laboratories’ Betaseron® (Interferon beta-1b),
is in the best interests of the entire multiple sclerosis community and a safeguard
for future drug development.
3/1/99 The incentive of
Orphan Drug exclusivity has enabled Biogen to fund important new research on AVONEX
and other products. Biogen reinvests about 30% of revenues into research for
new compounds, many of which have potential to provide new treatment options
for people with MS
The Avonex Support Line 1-800-456-2255 will be happy
to answer any questions you may have.
2/01 The purpose of this study was
to compare magnetic resonance imaging (MRI)
features and proton MR spectroscopy (1H-MRS) patterns of multiple sclerosis
(MS) plaques in order to define the metabolic substrate in different lesion
subtypes.
2/9/00 Department of Neurology
and Neurosurgery, Montreal-Neurological Institute, McGill University, Canada.
A patient was followed after the new onset of hemiparesis from relapse of MS
with serial MR spectroscopy and functional MRI. The association of clinical
improvement with recovery of N-acetylhtmlartate, a marker of neuronal integrity,
and progressive reduction of abnormally large functional MRI cortical activation
with movement demonstrates that dynamic reorganization of the motor cortex accompanies
remission of MS.
2/6/00 Imaging and pathomorphological studies
in multiple sclerosis suggest that Axonal
injury and axonal loss are playing a crucial role in those with persistent
disability and long-standing disease.
2/00 Spinal
cord Axonal Loss in multiple sclerosis: a post-mortem
study.
4/00 Clinical
Trial
2/9/00 Effect of
Interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity
on MRI. UBC MS/MRI Analysis Group and the MS Study Group.
10/13/99 COPAXONE(R)
and Betaseron(R) significantly reduced relapses in patients with relapsing-remitting
multiple sclerosis, while patients on Avonex(R) failed to show a statistically
significant therapeutic effect in this 12-month treatment study.
WAYNE, Pa., Jan. 19 /PRNewswire/ -- Afferon
Corporation today announced that it is beginning a U.S. Phase II clinical trial
for its lead product, RTX(TM) (resiniferatoxin) Topical
Solution, for the treatment of overactive bladder.
8/13/98 Just as a cardiac pacemaker helps maintain
a steady heartbeat, a new Bladder Pacemaker helps men and women
with debilitating bladder problems regain control of this vital function, according
to UCSF Stanford Health Care physicians, who pioneered the technology.
Characterization
of Differences between multiple sclerosis and normalBRAIN CELL TRANSPLANT
In an experiment that offers hope to patients
with multiple sclerosis and similar disorders, scientists have managed to get
transplanted
brain cells to disperse and travel widely throughout the brain, according to a
report in this month's Annals of Neurology, the scientific journal of the American
Neurological Association and the Child Neurology Society.
6/99 To investigate whether the localization of
multiple sclerosis (MS), the duration of the disease, and the level of neurologic
functioning in patients with MS predispose them to disturbed Breathing
Control .
1/2000 The recent issue
of BMJ published a paper calling for a more rationale debate on the use of cannabis. For over a decade there have been
anecdotal and clinical reports on the usefulness of cannabis preparations in
treating conditions like nausea, glaucoma, and multiple
sclerosis.
CEREBRAL ATROPHY
4/00
Progressive Cerebral Atrophy in MS: a serial
study using registered, volumetric MRI.
Cortical
cerebral Metabolism correlates with MRI lesion
load and cognitive dysfunction in MS.
CHLAMYDIA PNEUMONIA
ST. PAUL, MN 1/2000 Researchers Say
Chlamydia Pneumoniae Does Not Play A Role In
MS
NASHVILLE, TN -- July 2, 1999 -- Could a common bacterium
be involved in the development of multiple sclerosis_ In this month's Annals
of Neurology, researchers report finding evidence of the bacterium Chlamydia
pneumoniae in all the multiple sclerosis (MS) patients
in their study.
Toronto (April 23, 1999) An agent that causes respiratory tract infections 1/25/99 18-month, placebo-controlled, double-blind
study to evaluate Cladribine in the treatment of 52 patients
with relapsing-remitting multiple sclerosis.
MS Center,
Georgetown University
1/99 Clinical Trials for Multiple Sclerosis
Multiple Sclerosis Clinical
Research Centers
The purpose of this Study was to illustrate how cognitive functioning evolves over time in patients
with multiple sclerosis.
3/7/01 Relapsing-remitting multiple sclerosis patients treated with
Copaxone® (glatiramer acetate fo injection) showed rapid effect on almost all MRI-monitored disease activity and burden of disease parameters. These parameters correlated with reduction in relapse rates compared to placebo, according to a multi-center, placebo-controlled study published
this month in the Annals of Neurology. The study found a 29 percent reduction in enhancing lesions compared with placebo.
3/1/99 Clinical Trials announced.
12/99 BIRMINGHAM, Ala., -- Researchers at UAB (University
of Alabama at Birmingham) have shown that by manipulating the
Immune System they can prevent or slow the progression of multiple sclerosis (MS)
in mice.
1/2000 The immune system is involved
in the pathophysiology of multiple sclerosis (MS)
but the initiating antigen(s) is not yet identified. Since
cytokines control both the intensity and the quality of the immune response
they may be relevant candidates for the genetic susceptibility to MS.
"Black holes" on an MRI
Diagnostic Tests for Multiple Sclerosis
1/99 Eliprodil
appears to help repair the Nerve Demyelination associated with Multiple Sclerosis,
researchers report EPIDEMIOLOGY
11/98 Among some 7500 respondents with known place of birth
who had completed a nationwide questionnaire survey for multiple sclerosis (MS)
in France in 1986, there were 260 born in former French North Africa (Algeria,
Morocco, Tunisia).
1/2000 Myelin-associated oligodendrocytic
basic protein (MOBP) is an abundant myelin constituent expressed exclusively
by oligodendrocytes, the myelin-forming cells of the CNS. We report that
MOBP causes experimental allergic encephalomyelitis and is associated with
multiple sclerosis.
ESTRIOL
4/29/99 Estriol
ameliorates autoimmune demyelinating disease: implications for multiple
sclerosis.
EYE
National EYE Institute..... Clinical
Trials See also Vision on Page
2 of Research
1/18/01
Acorda Therapeutics announced today that it has begun a Phase 2 clinical study
of its lead product, Fampridine-SR, for
multiple sclerosis (MS).
1/2000 Chronic
fatigue syndrome is defined as idiopathic chronic fatigue plus any four
of eight symptoms: fatigue lasting more than 24 hours following exercise; memory
or concentration problems; tiredness upon waking in the morning; a sore throat;
tender cervical or axillary lymph nodes; muscle aches; joint pain; and headaches.
When a Molecular Factor normally found in the
nervous system is damaged or missing, nerve cells in the brain and body begin
to degenerate, according to a new study in mice.
2/00 GGF2 diminishes autoimmune
demyelination, promotes oligodendrocyte progenitor expansion, and enhances remyelination.
12/98 Cambridge NeuroScience and its academic
collaborators have generated impressive data demonstrating the unique mechanism
by which GGF2 stimulates
the remyelination of nerve cells,'' said David Lowe, Ph.D., head of CNS research
at Bayer. ``The companies have worked together in developing a manufacturing
process for the molecule.''
2/01 Sibling Risk for MS
3/98 ST. PAUL, MN -- March 23, 1998 -- A new study helps
determine the risk of developing multiple sclerosis (MS) for
SIBLINGS
of MS patients. The study is published in this month’s issue of Neurology
12/28/99 Two of the three studies
concerned a drug that blocks Glutamate, a chemical that normally transmits information from one nerve cell
to another. Levels of glutamate have been found to be increased in patients
with MS.
Declaration of Helsinki Recommendations
guiding physicians in biomedical research involving human subjects. Adopted
by the 18th World Medical Assembly, Helsinki Finland, June 1964 amended by the
29th World Medical Assembly, Tokyo, Japan, October 1975 35th World Medical Assembly,
Venice, Italy, October 1983 and the 41st World Medical Assembly, Hong Kong,
September 1989.
6/14/99 It is apparent that Critical Medical Decisions for an entire
generation of
American children are being made by small committees whose members have
incestuous ties with
agencies that stand to gain power, or manufacturers that stand to gain enormous
profits, from the policy that is made.
8/18/98 Reports linking Hepatitis B vaccination
to multiple sclerosis are is not confirmed. Studies are being conducted
in the US and Europe.
1/9/97 We are trying to identify more patients with
autoimmune disorders that might be related to the Hepatitis
B Vaccine in order to find a better way to prevent, diagnose, and treat such
reactions. Since it is clearly established that this vaccine (or the virus infection
itself) may cause MS like symptoms, your information could be a great help
for our ongoing research.
10/19/98 Have they found a
Viral Link to MS_ Dr. Konstance K. Knox of the Institute for Viral Pathogenesis
in Milwaukee, Wisconsin, and colleagues at the American Neurological Association
report a study may point in that direction. Knox said "the study cannot
conclusively determine whether HHV-6 is a cause or effect of the disease."
11/24/97 Specualtion: A strain of Reactivated
Herpes virus may be associated with multiple sclerosis
(MS), an autoimmune disorder in which the body attacks its own tissues.
06/99 ST. PAUL, MN -- Ibuprofen has been shown to reduce the "flu-like" side effects of the drug interferon
beta-1b, an effective treatment for multiple sclerosis attacks, according to
a study in the June issue of Neurology, the scientific journal of the American
Academy of Neurology.
10/00 A randomized, double-blinded,
placebo-controlled trial of
IV immunoglobulin (IVIg) was performed in patients with MS who
had persistent muscle weakness that had been stable for between 4 and
18 months to determine whether this would improve muscle strength
(primary outcome: isometric muscle strength). Patients received
either IVIg (0.4 g/kg) or placebo daily for 5 days, then single
infusions every 2 weeks for 3 months (total, 11 infusions).
7/99 Administration of high-dose
intravenous immunoglobulins
has become one of the most successful new treatment regimens for demyelinating
diseases.
4/98 In an attempt to prevent exacerbations of multiple
sclerosis, Immunoglobulin Therapy was combined with
azathioprine (AZA). Intravenous immunoglobulin (i.v.IG) 2 g/kg was given in
divided doses over 3 consecutive days followed by monthly booster doses (0.2
g/kg) for 3 years to 38 patients with relapsing-remitting multiple sclerosis
(MS).
7/98 IgG and MS . Medline Abstract
3/3/97 Monthly intravenous Immunoglobulin
(IVIg) administration to patients with relapsing-remitting
multiple sclerosis (MS) improves "...the course of clinical disability and reduce[s]
the frequency of relapses."
1/23/01 Reprogramming
the Immune System
3/10/97 Influenza Vaccines can be safely administered
to patients with multiple sclerosis, according to an article in Neurology.
2/25/99 Calypte Biomedical Corp. said Thursday its
partly owned affiliate, Pepgen Corp., will begin Phase I clinical trials of
its oral interferon, Interferon Tau, in multiple
sclerosis patients.
NEXT: RESEARCH....PAGE 2
| Home | Doctors | Faqs | Library | Family | Boards | Forums | Webcast | Exchange | Support Group |
|
Your Multiple Sclerosis
Resource
|
International
MS Support Foundation |
|
Bluedomino A company with a heart who didn't think twice about helping with our efforts. Thank you staff for all of your helpful online support. Please show your appreciation by contacting them for your Internet needs. |
Copyright © 1996-2002 International MS Support Foundation |
Sponsored by public
contributions, a grant from Biogen
and long dedicated hours by volunteers with multiple sclerosis.
|
|
Email Jean ©1996-2002 International MS Support Foundation. All rights reserved. Disclaimer: This material is provided as general medical information only and may not include all side effects or details relevant to a particular individual's treatment. Answers are not intended as advice for individual patients; please contact your own physician/neurologist for specific recommendations. |
||